Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 41kWORD 18k
9 January 2019
Question for written answer E-000073-19
to the Commission
Rule 130
Kateřina Konečná (GUE/NGL)

 Subject:  Drugs to treat dry eye syndrome
 Answer in writing 

Dry eye syndrome is now a relatively common condition, characterised by a strong feeling of discomfort and inflammation of the eyes. However, constant eye irritation could cause damage to the surface of the eye. The condition appears among all age groups, but it particularly affects women during the menopause. Failure to take the condition seriously and improper treatment can have drastic consequences in the form of corneal scarring and ulceration.

The Lifitegrast/Xiidra drugs are effective in treating dry eye syndrome. Unfortunately, whereas these drugs are available in the USA, they are not yet available on the EU marketplace.

Could the Commission therefore say whether an EU registration procedure for these drugs has been launched, and when these drugs are expected to be available for patients in the EU suffering from this serious condition?

Original language of question: CS 
Last updated: 23 January 2019Legal notice - Privacy policy